Hypericum perforatum: Traditional uses, clinical trials, and drug interactions

Hypericum perforatum (Hypericaceae), known as Saint John’s wort (SJW), has been used in different systems of traditional medicine such as Chinese traditional medicine, Greek traditional medicine, and Islamic traditional medicine. The plant and its active constituents such as hyperforin and hypericin have a wide range of medicinal uses, particularly as anti-depressant, wound-healing, and antibacterial agents. In recent decades, many clinical trials have been performed to investigate the safety and efficacy of this medicinal plant. However, to the best on our knowledge, there is no comprehensive review article in this regard. In the current study, we aim to have a comprehensive review of the clinical trials of SJW to evaluate its efficacy and safety as well as its application in traditional medicine. Clinical studies investigating the safety, interactions, and efficacy of SJW were identified and summarized, including contributions from 2000 until December 2021. According to the results, these clinical studies were divided into three main categories based on the type of disease: psychiatric, endocrine, and skin problems. Important details of the studies, including the type and duration of the study, the type and percentage of the effective compounds or the extract used, the number of patients, and the obtained results were also discussed. In addition, co-administration and drug interaction of SJW with other drugs were summarized. SJW is a valuable medicinal plant, especially for psychiatric disorders. However, precautions should be taken while administrating the plant.

[1]  M. Bahmani,et al.  Phytotherapy for wound healing: The most important herbal plants in wound healing based on Iranian etnobotanical documents. , 2020, Mini reviews in medicinal chemistry.

[2]  F. Altan,et al.  Hypericum perforatum L.: a medicinal plant with potential as a curative agent against obesity-associated complications , 2020, Molecular Biology Reports.

[3]  Huafu Chen,et al.  Improved Resting-State Functional Dynamics in Post-stroke Depressive Patients After Shugan Jieyu Capsule Treatment , 2020, Frontiers in Neuroscience.

[4]  W. Pan,et al.  The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke – A randomized clinical trial , 2020 .

[5]  C. Long,et al.  Ethnopharmacology of Hypericum species in China: A comprehensive review on ethnobotany, phytochemistry and pharmacology. , 2020, Journal of ethnopharmacology.

[6]  E. Kharasch,et al.  Influence of St. John’s Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects , 2019, Anesthesiology.

[7]  Yudong Ren,et al.  Antiviral Activity Against Infectious Bronchitis Virus and Bioactive Components of Hypericum perforatum L. , 2019, Front. Pharmacol..

[8]  P. Abedi,et al.  The effect of Hypericum perforatum on postmenopausal symptoms and depression: A randomized controlled trial. , 2019, Complementary therapies in medicine.

[9]  S. Krähenbühl,et al.  No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P‐glycoprotein , 2019, Planta Medica.

[10]  Nathaniel J. S. Ashby,et al.  The acute effect of Hypericum perforatum on short-term memory in healthy adults , 2018, Psychopharmacology.

[11]  W. Haefeli,et al.  Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided , 2018, British journal of clinical pharmacology.

[12]  F. Di Pierro,et al.  Role in depression of a multi-fractionated versus a conventional Hypericum perforatum extract. , 2018, Panminerva medica.

[13]  M. Rafieian,et al.  The effect of Achillea millefolium and Hypericum perforatum ointments on episiotomy wound healing in primiparous women , 2018, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[14]  P. Najafizadeh,et al.  The impact of topical Saint John's Wort (Hypericum perforatum) treatment on tissue tumor necrosis factor-alpha levels in plaque-type psoriasis: A pilot study , 2017, Journal of postgraduate medicine.

[15]  P. Fahey,et al.  Combined Lifestyle and Herbal Medicine in Overweight Women with Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial , 2017, Phytotherapy research : PTR.

[16]  Namita Hegde,et al.  A current update on phytochemistry, pharmacology and herb–drug interactions of Hypericum perforatum , 2017, Phytochemistry Reviews.

[17]  Q. Ng,et al.  Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. , 2017, Journal of affective disorders.

[18]  Yuanhua Liu,et al.  The preventive effects of hyperoside on lung cancer in vitro by inducing apoptosis and inhibiting proliferation through Caspase-3 and P53 signaling pathway. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  O. Sytar,et al.  Antifungal properties of hypericin, hypericin tetrasulphonic acid and fagopyrin on pathogenic fungi and spoilage yeasts , 2016, Pharmaceutical biology.

[20]  A. Dias,et al.  Neuroprotective Activity of Hypericum perforatum and Its Major Components , 2016, Front. Plant Sci..

[21]  E. Seifritz,et al.  Efficacy of Hypericum extract WS® 5570 compared with paroxetine in patients with a moderate major depressive episode – a subgroup analysis , 2016, International journal of psychiatry in clinical practice.

[22]  M. Maleki,et al.  Effect of Hypericum perforatum Aqueous Extracts on Serum Lipids, Aminotransferases, and Lipid Peroxidation in Hyperlipidemic Rats , 2016, Research in cardiovascular medicine.

[23]  W. Haefeli,et al.  St. John’s wort treatment in women bears risks beyond pharmacokinetic drug interactions , 2016, Archives of Toxicology.

[24]  D. Muñoz,et al.  Development of a Novel Formulation with Hypericin To Treat Cutaneous Leishmaniasis Based on Photodynamic Therapy in In Vitro and In Vivo Studies , 2015, Antimicrobial Agents and Chemotherapy.

[25]  K. Højlund,et al.  Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. , 2015, British journal of clinical pharmacology.

[26]  Xiao-lin Zhang,et al.  Effect of Hypericum perforatum L. Extract on Insulin Resistance and Lipid Metabolic Disorder in High-Fat-Diet Induced Obese Mice , 2014, Phytotherapy research : PTR.

[27]  T. Scriba,et al.  St John's Wort (Hypericum perforatum L.) Photomedicine: Hypericin-Photodynamic Therapy Induces Metastatic Melanoma Cell Death , 2014, PloS one.

[28]  G. di Perri,et al.  Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. , 2014, The Journal of antimicrobial chemotherapy.

[29]  Christoph M Schempp,et al.  Topical Application of St. Johnʼs Wort (Hypericum perforatum) , 2013, Planta Medica.

[30]  B. Božin,et al.  Impact of Origin and Biological Source on Chemical Composition, Anticholinesterase and Antioxidant Properties of Some St. John’s Wort Species (Hypericum spp., Hypericaceae) from the Central Balkans , 2013, Molecules.

[31]  G. Stojanović,et al.  Do other Hypericum species have medical potential as St. John's wort (Hypericum perforatum)? , 2013, Current medicinal chemistry.

[32]  W. Wijns,et al.  St. John’s Wort in Patients Non-responders to Clopidogrel Undergoing Percutaneous Coronary Intervention: a Single-Center Randomized Open-Label Trial (St. John’s Trial) , 2013, Journal of Cardiovascular Translational Research.

[33]  J. Schellens,et al.  The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel , 2013, Clinical Pharmacokinetics.

[34]  P. Neuvonen,et al.  St John’s wort greatly decreases the plasma concentrations of oral S‐ketamine , 2012, Fundamental & clinical pharmacology.

[35]  B. Krick,et al.  Herbal triplet in treatment of nervous agitation in children , 2012, Wiener Medizinische Wochenschrift.

[36]  W. Haefeli,et al.  Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity , 2012, European Journal of Clinical Pharmacology.

[37]  D. Mischoulon,et al.  St John’s Wort (Hypericum perforatum) versus Sertraline and Placebo in Major Depressive Disorder: Continuation Data from a 26-Week RCT , 2012, Pharmacopsychiatry.

[38]  P. Najafizadeh,et al.  The evaluation of the clinical effect of topical St Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: A pilot study , 2012, The Australasian journal of dermatology.

[39]  Mansoor M Ahmed,et al.  Efficacy and tolerability assessment of a topical formulation containing copper sulfate and hypericum perforatum on patients with herpes skin lesions: a comparative, randomized controlled trial. , 2012, Journal of drugs in dermatology : JDD.

[40]  L. Davids,et al.  The Anticancer Activity of Hypericin in Photodynamic Therapy , 2012 .

[41]  M. Echizenya,et al.  Drug interaction between St John’s wort and zolpidem in healthy subjects , 2011, Journal of clinical pharmacy and therapeutics.

[42]  Ya-li Liu,et al.  The Pregnane X Receptor Agonist St John’s Wort Has No Effects on the Pharmacokinetics and Pharmacodynamics of Repaglinide , 2011, Clinical pharmacokinetics.

[43]  K. Stade,et al.  Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[44]  R. Giugliano,et al.  Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. , 2011, Critical pathways in cardiology.

[45]  F. Ghaffarpasand,et al.  Hypericum perforatum for the treatment of premenstrual syndrome , 2011, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[46]  M. Rubenfire,et al.  The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity , 2011, Journal of cardiovascular pharmacology.

[47]  P. Neuvonen,et al.  St John's wort greatly reduces the concentrations of oral oxycodone , 2010, European journal of pain.

[48]  E. Ernst,et al.  Hypericum for fatigue – a pilot study , 2010 .

[49]  S. Chun,et al.  The Effects of St. John's Wort on Premenstrual Syndrome in Single Women: A Randomized Double-Blind, Placebo-Controlled Study , 2010 .

[50]  H. Lei,et al.  Effect of St. John’s wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[51]  M. Waterman,et al.  The Efficacy of Hypericum perforatum (St John’s Wort) for the Treatment of Premenstrual Syndrome , 2010, CNS drugs.

[52]  H. Tabatabaee,et al.  Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study , 2010, Menopause.

[53]  H. Niederhofer.  St. John's wort may improve some symptoms of attention-deficit hyperactivity disorder , 2010, Natural product research.

[54]  E. Akkol,et al.  Investigations on the in vivo wound healing potential of Hypericum perforatum L. , 2010, Journal of ethnopharmacology.

[55]  M. Keck,et al.  A Hypericum Extract in the Treatment of Depressive Symptoms in Outpatients: An Open Study , 2010, Complementary Medicine Research.

[56]  W. Haefeli,et al.  Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity , 2010, Clinical pharmacology and therapeutics.

[57]  Talat Khadivzadeh,et al.  The effect of Hypericum perforatum on the wound healing and scar of cesarean. , 2010, Journal of alternative and complementary medicine.

[58]  R. Clarke.  Are modern preparation methods compromising the efficacy of Chinese herbal medicines? An investigation using Guan Ye Lian Qiao (Hypericum perforatum L.). , 2010 .

[59]  J. Stockman.  Hypericum perforatum (St John's Wort) for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Randomized Controlled Trial , 2010 .

[60]  F. Fahami,et al.  A comparative study on the effects of Hypericum Perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers , 2010, Iranian journal of nursing and midwifery research.

[61]  H. Niederhofer.  St John's Wort treating patients with autistic disorder , 2009, Phytotherapy research : PTR.

[62]  P. Agostinis,et al.  The multifaceted photocytotoxic profile of hypericin. , 2009, Molecular Pharmaceutics.

[63]  A. Brattström.  Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression. , 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[64]  J. K. Gour,et al.  St. John’s Wort (Hypericum perforatum) , 2019, Nonvitamin and Nonmineral Nutritional Supplements.

[65]  Xue-hong Wang,et al.  Anti-influenza A virus effect of Hypericum perforatum L. extract , 2009, Virologica Sinica.

[66]  D. Rader,et al.  Reduced efficacy of rosuvastatin by St. John's Wort. , 2009, The American journal of medicine.

[67]  H. Burger,et al.  Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial , 2009, Menopause.

[68]  H. Möller,et al.  Continuation and long-term maintenance treatment with Hypericum extract WS® 5570 after recovery from an acute episode of moderate depression — A double-blind, randomized, placebo controlled long-term trial , 2008, European Neuropsychopharmacology.

[69]  G. Lodi,et al.  Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. , 2008, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[70]  D. Kacerovská,et al.  Photodynamic Therapy of Nonmelanoma Skin Cancer with Topical Hypericum perforatum Extract—A Pilot Study , 2008, Photochemistry and photobiology.

[71]  G. Kundt,et al.  No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers , 2008, European Journal of Clinical Pharmacology.

[72]  M. Fava,et al.  Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder , 2008, Neuropsychobiology.

[73]  Edward C. Bell,et al.  Complementary and Alternative Medicine: Lack of Pharmacokinetic Interaction Between St. John's Wort and Prednisone , 2007, The Annals of pharmacotherapy.

[74]  R. Eggertsen,et al.  Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia , 2007, European Journal of Clinical Pharmacology.

[75]  Edward C. Bell,et al.  Effects of St. John's Wort Supplementation on Ibuprofen Pharmacokinetics , 2007, The Annals of pharmacotherapy.

[76]  A. Portolés,et al.  Effects of Hypericum perforatum on Ivabradine Pharmacokinetics in Healthy Volunteers: An Open‐Label, Pharmacokinetic Interaction Clinical Trial , 2006, Journal of clinical pharmacology.

[77]  S. Kasper,et al.  Superior efficacy of St John's wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298] , 2006 .

[78]  L. Taylor,et al.  St John's wort versus placebo in obsessive–compulsive disorder: results from a double-blind study , 2005, International clinical psychopharmacology.

[79]  J. Donovan,et al.  Effects of St John's wort (Hypericum perforatum L.) extract on plasma androgen concentrations in healthy men and women: a pilot study , 2005, Phytotherapy research : PTR.

[80]  M. Fava,et al.  A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder , 2005, Journal of clinical psychopharmacology.

[81]  Steven Edward Kern,et al.  Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. , 2005, Contraception.

[82]  A. Szegedi,et al.  Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine , 2005, BMJ : British Medical Journal.

[83]  L. Taylor,et al.  St. John's Wort Versus Placebo in Social Phobia: Results From a Placebo-Controlled Pilot Study , 2005, Journal of clinical psychopharmacology.

[84]  M. Egorin,et al.  Effect of St John's Wort on imatinib mesylate pharmacokinetics , 2004, Clinical pharmacology and therapeutics.

[85]  K. Budde,et al.  Hyperforin content determines the magnitude of the St John's Wort–cyclosporine drug interaction , 2004, Clinical pharmacology and therapeutics.

[86]  H. Murck,et al.  Treatment of Somatoform Disorders With St. John's Wort: A Randomized, Double-Blind and Placebo-Controlled Trial , 2004, Psychosomatic medicine.

[87]  B. Uehleke,et al.  Effect of St John's Wort Dose and Preparations on the Pharmacokinetics of Digoxin , 2004, Clinical pharmacology and therapeutics.

[88]  Honghao Zhou,et al.  The Influence of St. John's Wort on CYP2C19 Activity with Respect to Genotype , 2004, Journal of clinical pharmacology.

[89]  R. Day,et al.  Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. , 2004, British journal of clinical pharmacology.

[90]  T. Baghai,et al.  Endocrinological Effects of High-Dose Hypericum perforatum Extract WS 5570 in Healthy Subjects , 2004, Neuropsychobiology.

[91]  M. Hebert,et al.  Effects of St. John's Wort (Hypericum perforatum) on Tacrolimus Pharmacokinetics in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[92]  T. Kotegawa,et al.  Effect of St. John's Wort on the Pharmacokinetics of Theophylline in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[93]  森本 卓哉.  Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers , 2004 .

[94]  Shiew-Mei Huang,et al.  The interaction between St John's wort and an oral contraceptive , 2003, Clinical pharmacology and therapeutics.

[95]  A. Wittkowsky.  Warfarin and Other Coumarin Derivatives: Pharmacokinetics, Pharmacodynamics, and Drug Interactions , 2003, Seminars in vascular medicine.

[96]  K. Budde,et al.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. , 2003, British journal of clinical pharmacology.

[97]  J. Verweij,et al.  Effects of St. John's wort on irinotecan metabolism. , 2002, Journal of the National Cancer Institute.

[98]  W. Wittkowski,et al.  Long-term effects of St. John’s wort and hypericin on monoamine levels in rat hypothalamus and hippocampus , 2002, Brain Research.

[99]  D. Back,et al.  CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[100]  R. Saller,et al.  A current review of the antimicrobial activity of Hypericum perforatum L. , 2001, Pharmacopsychiatry.

[101]  T. Jensen,et al.  St. John's wort has no effect on pain in polyneuropathy , 2001, Pain.

[102]  J. Greeson,et al.  St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature , 2001, Psychopharmacology.

[103]  S. Piscitelli,et al.  Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers , 2000, Clinical pharmacology and therapeutics.

[104]  G. Gerken,et al.  Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. , 2000, Journal of hepatology.

[105]  L. Taylor,et al.  An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. , 2000, The Journal of clinical psychiatry.

[106]  R. Obach,et al.  Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. , 2000, The Journal of pharmacology and experimental therapeutics.

[107]  L. Moore,et al.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Falloon,et al.  Indinavir concentrations and St John's wort , 2000, The Lancet.

[109]  F. Ruschitzka,et al.  Acute heart transplant rejection due to Saint John's wort , 2000, The Lancet.

[110]  P. Cowen,et al.  Antidepressant-like effect of Hypericum perforatum (St John’s wort) on the sleep polysomnogram , 1998, Psychopharmacology.

[111]  H. Wagner,et al.  Inhibition of MAO by Fractions and Constituents of Hypericum Extract , 1994, Journal of geriatric psychiatry and neurology.